Human Phenotype Ontology 
Grandparent Node:
expand
Behavioral abnormality (HP:0000708)help
Parent Node:
expand
Impairment in personality functioning (HP:0031466)help
..Starting node
..expand
Disinhibition (HP:0000734)help
Term ID: 734
Name: Disinhibition
Synonym: Disinhibition
Definition: A lack of restraint manifested in several ways, including disregard for social conventions, impulsivity, and poor risk assessment.
Comments:
Reference: HP:0000734
Genes and Diseases:
 
       Child Nodes:
........expandRisk taking (HP:0031472) help
........expandImpulsivity (HP:0100710) help

 Sister Nodes: 
..expandAbnormal fear/anxiety-related behavior (HP:0100852) help
..expandAnhedonia (HP:0012154) help
..expandBipolar affective disorder (HP:0007302) help
..expandDepression (HP:0000716) help
..expandEmotional lability (HP:0000712) help
..expandHostility (HP:0031473) help
..expandInappropriate behavior (HP:0000719) help
..expandLow self esteem (HP:0031469) help
..expandNegative affectivity (HP:0031467) help
..expandPersonality disorder (HP:0012075) help
..expandSeparation insecurity (HP:0031468) help
InputHPO IDHPO termDistanceGeneGene id entrezDiseaseIdDiseaseNameDiseaseMIMConceptIDSourceTypical associationHGMD variantsClinVar variantsHGNC IDGeneMIM
 
HPO disease - gene - phenotype typical associations:
HP:0000734HP:0000734Disinhibition0ABCA7 CL E G H103471020ORPHA114837605414
HP:0000734HP:0000734Disinhibition0APP CL E G H3511020ORPHA1404620104760
HP:0000734HP:0000734Disinhibition0C9orf72 CL E G H203228275864ORPHA117328337614260
HP:0000734HP:0000734Disinhibition0CHMP2B CL E G H25978275864ORPHA114124537609512
HP:0000734HP:0000734Disinhibition0CHMP2B CL E G H25978600795Frontotemporal Dementia, Chromosome 3-Linked600795C1833296OMIM114124537609512
HP:0000734HP:0000734Disinhibition0FMR1 CL E G H2332300623Fragile X tremor/ataxia syndrome300623C1839780OMIM13383775309550
HP:0000734HP:0000734Disinhibition0FTL CL E G H2512606159Neuroferritinopathy606159C1853578OMIM11513999134790
HP:0000734HP:0000734Disinhibition0GRN CL E G H2896275864ORPHA14174601138945
HP:0000734HP:0000734Disinhibition0GRN CL E G H2896607485Frontotemporal dementia, ubiquitin-positive607485C1843792OMIM14174601138945
HP:0000734HP:0000734Disinhibition0MAPT CL E G H4137275864ORPHA15146893157140
HP:0000734HP:0000734Disinhibition0MAPT CL E G H4137600274Frontotemporal dementia600274C0338451OMIM15146893157140
HP:0000734HP:0000734Disinhibition0MAPT CL E G H4137172700Pick's disease172700C0236642OMIM15146893157140
HP:0000734HP:0000734Disinhibition0PSEN1 CL E G H5663275864ORPHA14529508104311
HP:0000734HP:0000734Disinhibition0PSEN1 CL E G H56631020ORPHA14529508104311
HP:0000734HP:0000734Disinhibition0PSEN1 CL E G H5663600274Frontotemporal dementia600274C0338451OMIM14529508104311
HP:0000734HP:0000734Disinhibition0PSEN1 CL E G H5663172700Pick's disease172700C0236642OMIM14529508104311
HP:0000734HP:0000734Disinhibition0PSEN2 CL E G H56641020ORPHA12379509600759
HP:0000734HP:0000734Disinhibition0SORL1 CL E G H66531020ORPHA132011185602005
HP:0000734HP:0000734Disinhibition0SPAST CL E G H6683182601Spastic paraplegia 4, autosomal dominant182601C1866855OMIM1101411233604277
HP:0000734HP:0000734Disinhibition0SQSTM1 CL E G H8878275864ORPHA154211280601530
HP:0000734HP:0000734Disinhibition0SQSTM1 CL E G H8878616437Frontotemporal dementia and/or amyotrophic lateral sclerosis 3616437C4225326OMIM154211280601530
HP:0000734HP:0000734Disinhibition0TARDBP CL E G H23435612069Amyotrophic lateral sclerosis type 10612069C2677565OMIM125911571605078
HP:0000734HP:0000734Disinhibition0TBK1 CL E G H29110616439Frontotemporal dementia and/or amyotrophic lateral sclerosis 4616439C4225325OMIM129411584604834
HP:0000734HP:0000734Disinhibition0TMEM106B CL E G H54664275864ORPHA18722407613413
HP:0000734HP:0000734Disinhibition0TOMM40 CL E G H104521020ORPHA11418001608061
HP:0000734HP:0000734Disinhibition0TREM2 CL E G H542092770ORPHA111017761605086
HP:0000734HP:0000734Disinhibition0TREM2 CL E G H54209275864ORPHA111017761605086
HP:0000734HP:0000734Disinhibition0TREM2 CL E G H542091020ORPHA111017761605086
HP:0000734HP:0000734Disinhibition0TYROBP CL E G H73052770ORPHA18512449604142
HP:0000734HP:0000734Disinhibition0TYROBP CL E G H7305221770Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy221770C1857316OMIM18512449604142
HP:0000734HP:0000734Disinhibition0VCP CL E G H7415275864ORPHA147312666601023
HP:0000734HP:0000734Disinhibition0VPS13A CL E G H23230200150Choreoacanthocytosis200150C0393576OMIM117351908605978
HP:0000734HP:0031472Risk taking1ABCA7 CL E G H103471020ORPHA114837605414
HP:0000734HP:0100710Impulsivity1ABCA7 CL E G H103471020ORPHA114837605414
HP:0000734HP:0100710Impulsivity1APP CL E G H3511020ORPHA1404620104760
HP:0000734HP:0031472Risk taking1APP CL E G H3511020ORPHA1404620104760
HP:0000734HP:0100710Impulsivity1C9orf72 CL E G H203228275864ORPHA117328337614260
HP:0000734HP:0031472Risk taking1C9orf72 CL E G H203228275864ORPHA117328337614260
HP:0000734HP:0031472Risk taking1CHMP2B CL E G H25978275864ORPHA114124537609512
HP:0000734HP:0100710Impulsivity1CHMP2B CL E G H25978275864ORPHA114124537609512
HP:0000734HP:0031472Risk taking1CHMP2B CL E G H25978600795Frontotemporal Dementia, Chromosome 3-Linked600795C1833296OMIM114124537609512
HP:0000734HP:0100710Impulsivity1CHMP2B CL E G H25978600795Frontotemporal Dementia, Chromosome 3-Linked600795C1833296OMIM114124537609512
HP:0000734HP:0031472Risk taking1FMR1 CL E G H2332300623Fragile X tremor/ataxia syndrome300623C1839780OMIM13383775309550
HP:0000734HP:0100710Impulsivity1FMR1 CL E G H2332300623Fragile X tremor/ataxia syndrome300623C1839780OMIM13383775309550
HP:0000734HP:0031472Risk taking1FTL CL E G H2512606159Neuroferritinopathy606159C1853578OMIM11513999134790
HP:0000734HP:0100710Impulsivity1FTL CL E G H2512606159Neuroferritinopathy606159C1853578OMIM11513999134790
HP:0000734HP:0031472Risk taking1GRN CL E G H2896275864ORPHA14174601138945
HP:0000734HP:0100710Impulsivity1GRN CL E G H2896275864ORPHA14174601138945
HP:0000734HP:0031472Risk taking1GRN CL E G H2896607485Frontotemporal dementia, ubiquitin-positive607485C1843792OMIM14174601138945
HP:0000734HP:0100710Impulsivity1GRN CL E G H2896607485Frontotemporal dementia, ubiquitin-positive607485C1843792OMIM14174601138945
HP:0000734HP:0031472Risk taking1MAPT CL E G H4137275864ORPHA15146893157140
HP:0000734HP:0100710Impulsivity1MAPT CL E G H4137275864ORPHA15146893157140
HP:0000734HP:0031472Risk taking1MAPT CL E G H4137600274Frontotemporal dementia600274C0338451OMIM15146893157140
HP:0000734HP:0100710Impulsivity1MAPT CL E G H4137600274Frontotemporal dementia600274C0338451OMIM15146893157140
HP:0000734HP:0031472Risk taking1MAPT CL E G H4137172700Pick's disease172700C0236642OMIM15146893157140
HP:0000734HP:0100710Impulsivity1MAPT CL E G H4137172700Pick's disease172700C0236642OMIM15146893157140
HP:0000734HP:0031472Risk taking1PSEN1 CL E G H56631020ORPHA14529508104311
HP:0000734HP:0100710Impulsivity1PSEN1 CL E G H5663275864ORPHA14529508104311
HP:0000734HP:0100710Impulsivity1PSEN1 CL E G H56631020ORPHA14529508104311
HP:0000734HP:0031472Risk taking1PSEN1 CL E G H5663275864ORPHA14529508104311
HP:0000734HP:0100710Impulsivity1PSEN1 CL E G H5663600274Frontotemporal dementia600274C0338451OMIM14529508104311
HP:0000734HP:0031472Risk taking1PSEN1 CL E G H5663600274Frontotemporal dementia600274C0338451OMIM14529508104311
HP:0000734HP:0031472Risk taking1PSEN1 CL E G H5663172700Pick's disease172700C0236642OMIM14529508104311
HP:0000734HP:0100710Impulsivity1PSEN1 CL E G H5663172700Pick's disease172700C0236642OMIM14529508104311
HP:0000734HP:0031472Risk taking1PSEN2 CL E G H56641020ORPHA12379509600759
HP:0000734HP:0100710Impulsivity1PSEN2 CL E G H56641020ORPHA12379509600759
HP:0000734HP:0031472Risk taking1SORL1 CL E G H66531020ORPHA132011185602005
HP:0000734HP:0100710Impulsivity1SORL1 CL E G H66531020ORPHA132011185602005
HP:0000734HP:0031472Risk taking1SPAST CL E G H6683182601Spastic paraplegia 4, autosomal dominant182601C1866855OMIM1101411233604277
HP:0000734HP:0100710Impulsivity1SPAST CL E G H6683182601Spastic paraplegia 4, autosomal dominant182601C1866855OMIM1101411233604277
HP:0000734HP:0031472Risk taking1SQSTM1 CL E G H8878275864ORPHA154211280601530
HP:0000734HP:0100710Impulsivity1SQSTM1 CL E G H8878275864ORPHA154211280601530
HP:0000734HP:0031472Risk taking1SQSTM1 CL E G H8878616437Frontotemporal dementia and/or amyotrophic lateral sclerosis 3616437C4225326OMIM154211280601530
HP:0000734HP:0100710Impulsivity1SQSTM1 CL E G H8878616437Frontotemporal dementia and/or amyotrophic lateral sclerosis 3616437C4225326OMIM154211280601530
HP:0000734HP:0100710Impulsivity1TARDBP CL E G H23435612069Amyotrophic lateral sclerosis type 10612069C2677565OMIM125911571605078
HP:0000734HP:0031472Risk taking1TARDBP CL E G H23435612069Amyotrophic lateral sclerosis type 10612069C2677565OMIM125911571605078
HP:0000734HP:0031472Risk taking1TBK1 CL E G H29110616439Frontotemporal dementia and/or amyotrophic lateral sclerosis 4616439C4225325OMIM129411584604834
HP:0000734HP:0100710Impulsivity1TBK1 CL E G H29110616439Frontotemporal dementia and/or amyotrophic lateral sclerosis 4616439C4225325OMIM129411584604834
HP:0000734HP:0031472Risk taking1TMEM106B CL E G H54664275864ORPHA18722407613413
HP:0000734HP:0100710Impulsivity1TMEM106B CL E G H54664275864ORPHA18722407613413
HP:0000734HP:0100710Impulsivity1TOMM40 CL E G H104521020ORPHA11418001608061
HP:0000734HP:0031472Risk taking1TOMM40 CL E G H104521020ORPHA11418001608061
HP:0000734HP:0031472Risk taking1TREM2 CL E G H542091020ORPHA111017761605086
HP:0000734HP:0100710Impulsivity1TREM2 CL E G H542091020ORPHA111017761605086
HP:0000734HP:0031472Risk taking1TREM2 CL E G H542092770ORPHA111017761605086
HP:0000734HP:0031472Risk taking1TREM2 CL E G H54209275864ORPHA111017761605086
HP:0000734HP:0100710Impulsivity1TREM2 CL E G H542092770ORPHA111017761605086
HP:0000734HP:0100710Impulsivity1TREM2 CL E G H54209275864ORPHA111017761605086
HP:0000734HP:0031472Risk taking1TYROBP CL E G H73052770ORPHA18512449604142
HP:0000734HP:0100710Impulsivity1TYROBP CL E G H73052770ORPHA18512449604142
HP:0000734HP:0031472Risk taking1TYROBP CL E G H7305221770Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy221770C1857316OMIM18512449604142
HP:0000734HP:0100710Impulsivity1TYROBP CL E G H7305221770Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy221770C1857316OMIM18512449604142
HP:0000734HP:0100710Impulsivity1VCP CL E G H7415275864ORPHA147312666601023
HP:0000734HP:0031472Risk taking1VCP CL E G H7415275864ORPHA147312666601023
HP:0000734HP:0100710Impulsivity1VPS13A CL E G H23230200150Choreoacanthocytosis200150C0393576OMIM117351908605978
HP:0000734HP:0031472Risk taking1VPS13A CL E G H23230200150Choreoacanthocytosis200150C0393576OMIM117351908605978
 
HPO disease - gene - phenotype less frequent non-typical associations:
HP:0000734HP:0000734Disinhibition0C9orf72 CL E G H203228275872ORPHA017328337614260
HP:0000734HP:0000734Disinhibition0CHCHD10 CL E G H400916275872ORPHA024815559615903
HP:0000734HP:0000734Disinhibition0FUS CL E G H2521275872ORPHA04094010137070
HP:0000734HP:0000734Disinhibition0SQSTM1 CL E G H8878275872ORPHA054211280601530
HP:0000734HP:0000734Disinhibition0TARDBP CL E G H23435275872ORPHA025911571605078
HP:0000734HP:0000734Disinhibition0TBK1 CL E G H29110275872ORPHA029411584604834
HP:0000734HP:0000734Disinhibition0VCP CL E G H7415275872ORPHA047312666601023
HP:0000734HP:0031472Risk taking1C9orf72 CL E G H203228275872ORPHA017328337614260
HP:0000734HP:0100710Impulsivity1C9orf72 CL E G H203228275872ORPHA017328337614260
HP:0000734HP:0031472Risk taking1CHCHD10 CL E G H400916275872ORPHA024815559615903
HP:0000734HP:0100710Impulsivity1CHCHD10 CL E G H400916275872ORPHA024815559615903
HP:0000734HP:0031472Risk taking1FUS CL E G H2521275872ORPHA04094010137070
HP:0000734HP:0100710Impulsivity1FUS CL E G H2521275872ORPHA04094010137070
HP:0000734HP:0100710Impulsivity1SQSTM1 CL E G H8878275872ORPHA054211280601530
HP:0000734HP:0031472Risk taking1SQSTM1 CL E G H8878275872ORPHA054211280601530
HP:0000734HP:0031472Risk taking1TARDBP CL E G H23435275872ORPHA025911571605078
HP:0000734HP:0100710Impulsivity1TARDBP CL E G H23435275872ORPHA025911571605078
HP:0000734HP:0031472Risk taking1TBK1 CL E G H29110275872ORPHA029411584604834
HP:0000734HP:0100710Impulsivity1TBK1 CL E G H29110275872ORPHA029411584604834
HP:0000734HP:0031472Risk taking1VCP CL E G H7415275872ORPHA047312666601023
HP:0000734HP:0100710Impulsivity1VCP CL E G H7415275872ORPHA047312666601023


Genes (87) :AARS ABCA7 AFF2 AMT AP3B2 APP ARV1 ATP6V1A C19ORF12 C9ORF72 C9orf72 CACNA1A CEP152 CHCHD10 CHD2 CHMP2B CLTC CNKSR2 CREBBP CYFIP2 DHDDS DNAJC13 DNM1 DNMT1 EEF1A2 EIF4G1 EP300 FGF12 FMR1 FTL FUS FUZ GABRB2 GBA GCSH GIGYF2 GLDC GRIN2D GRN HCN1 HIVEP2 KANSL1 KCNA2 KCNB1 KNL1 LRRK2 MAGEL2 MAOA MAPT NECAP1 NTRK2 NUS1 PANK2 PHIP PLA2G6 PPP3CA PSEN1 PSEN2 SCN3A SCN8A SLC13A5 SLC1A2 SLC6A1 SNCA SORL1 SPAST SQSTM1 STXBP1 SYNGAP1 SYNJ1 SZT2 TARDBP TBK1 TMEM106B TMEM240 TOMM40 TRAK1 TREM2 TYROBP UBA5 VANGL1 VCP VPS13A VPS35 WDR62 WWOX YWHAG

Diseases (38) :1020 275872 275864 600795 300623 606159 607485 600274 172700 182601 616437 612069 616439 2770 221770 200150 442835 309548 605899 614298 614852 1942 617854 301008 180849 411602 614116 3027 616977 610443 604321 615547 300615 216873 617991 610217 607454 604317
 

Human Phenotype Ontology(HPO) is developed by the Human Phenotype Ontology Consortium. The version used here is August 2021 release.